Research

Research Outcomes: Advancing Research to Improve Treatment

by St. Baldrick's Foundation
November 8, 2021

Your generosity makes a difference for kids with cancer. This edition of the St. Baldrick’s Foundation Research Outcomes recognizes research that is making treatments less toxic, evaluating new drugs, and working to prevent late effects. Thank you for making research possible.

Lab Equipment with text: Research Outcomes

Read more »


Advocacy

FDA Acts on Latest Childhood Cancer Drug Shortage

by Kathleen Ruddy, CEO, St. Baldrick's Foundation
February 7, 2014

Join Speak Up for Kids’ Cancer to receive childhood cancer advocacy news and updates.

daunorubicin-drug-shortage-update
Last November, we reported on a shortage of the generic, sterile injectable chemotherapy drug, daunorubicin, that is used to treat children with acute myeloid leukemia (AML) as well as acute lymphoblastic leukemia (ALL).

Pediatric oncologists have depended on daunorubicin  as a go-to treatment for kids with these leukemias for nearly 40 years.  The fact that it has been difficult for many hospitals to obtain caused alarm bells to go off within the pediatric cancer community and sparked an inquiry from Congress to the U.S. Food and Drug Administration (FDA).

Now, roughly two months after the FDA received a letter about the shortage of daunorubicin from Rep. Michael McCaul (R-Texas) and Rep. Chris Van Hollen (D-Md.), co-chairs of the Congressional Childhood Cancer Caucus, the agency has replied.

Read more »


Advocacy

Pediatric Drug Shortage Crisis Ongoing

by St. Baldrick's Foundation
February 23, 2012

DrugShortageOngoing-05-10.jpg

Please ask Congress to act now!

The pediatric drug shortage crisis is ongoing. Recent FDA actions are providing some short-term solutions but the crisis remains.

At an FDA briefing on February 21, 2012, Dr. Peter Adamson, Chair of the Children’s Oncology Group called upon policymakers to act swiftly on the drug shortage bills already introduced in Congress.

Read more »


Advocacy

Mom Speaks Up on Drug Shortage

by St. Baldrick's Foundation
February 21, 2012

MomSpeaksUp-07.jpg

Thanks to you, children with leukemia and osteosarcoma are more optimistic about their future than they were a week ago.

A short term solution to a much larger problem is in place today as the FDA approved the import of methotrexate (MTX) from the Australian branch of Hospira, Inc. and approved an application from pharmaceutical company, APP, to begin manufacturing preservative-free MTX in the U.S.

Read more »


Advocacy

UPDATE on Childhood Cancer Drug Shortage

by Kathleen Ruddy, CEO, St. Baldrick's Foundation
February 17, 2012

MethotrexateUpdate1.jpg

The quick and unified action of the childhood cancer community — including thousands of messages to Congress from the St. Baldrick’s community — helped spur the immediate increase in production of methotrexate, a leading drug in the treatment of acute lymphoblstic leukemia (ALL), but the production increase of methotrexate is only a temporary solution – a drug shortage still looms for at least twelve drugs critical to the treatment of childhood cancer.

Read more »


Advocacy

Childhood Cancer Drug Shortage

by St. Baldrick's Foundation
February 14, 2012

DrugShortage-05.jpg

 

** TAKE ACTION NOW **

 

Children with cancer are facing a crisis – a drug shortage that could threaten thousands of lives. You can “Speak Up” and demand change. Methotrexate, the most-advanced and most-effective drug to treat acute lymphoblastic leukemia (ALL), the most common form of childhood cancer, as well as other types of cancer, is in short supply.

Read more »